( hina by filing for import verification....)Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,,Its New Long Acting Drug For Erectile Dysfunction,Health

China's pharmaceutical market has expanded dramatically in the past decade, and is currently valued at over US$25 billion. It has been reported that as many as 50 percent of Chinese men aged between 40 and 70 are suffering from ED, comparable to other countries. Udenafil is expected to participate in a growing prescription ED market by offering a long-acting and safe product that will compete with Viagra(R) (Pfizer), Cialis(R) (Lilly) and Levitra(R) (Bayer/GSK/Schering-Plough).

About Dong-A PharmTech Co., Ltd.

Dong-A PharmTech is a late-stage pharmaceutical company incorporated in Korea, focused on the development and commercialization of udenafil worldwide excluding Korea.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.

    Contact:

    Mr. Chan Won OH

    General Manager, International Product Development Team

    252, Yongdu-Dong, Dongdaemun-Ku

    Seoul 130-078, Korea

    Tel:  +82 2 920 8220

    Fax:  +82 2 925 4026

    Email: 

CONTACT: Mr. Chan Won OH, General Manager, International ProductDevelopment Team of Dong-A PharmTech Co., Ltd., +82 2 920 8220, Fax, +82 2925 4026, ocw@donga.co.kr

Terms and co
'"/>